Advertisement
Advertisement
U.S. Markets open in 25 mins
Advertisement
Advertisement
Advertisement
Advertisement

Athenex, Inc. (ATNX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.1826+0.0025 (+1.39%)
At close: 04:00PM EST
0.1842 +0.00 (+0.88%)
Pre-Market: 08:49AM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.1801
Open0.1811
Bid0.1814 x 800
Ask0.1875 x 1200
Day's Range0.1800 - 0.1900
52 Week Range0.1180 - 1.2000
Volume697,674
Avg. Volume4,103,088
Market Cap19.962M
Beta (5Y Monthly)1.25
PE Ratio (TTM)N/A
EPS (TTM)-1.7180
Earnings DateMar 13, 2023 - Mar 17, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.33
  • GlobeNewswire

    Athenex Announces MHRA Decision on Oral Paclitaxel

    MHRA denies Oral Paclitaxel for metastatic breast cancer based solely on chemistry, manufacturing and control (CMC) issuesAthenex plans to request a review of the MHRA decision by an independent panel The MHRA application was supplemented with safety data from the iSPY 2 study and no major clinical efficacy or safety concerns were expressed BUFFALO, N.Y., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, a

  • American City Business Journals

    Athenex to close Clarence plant, lay off 92 employees

    Athenex Pharma Solutions will close its plant on Main Street in Clarence, according to a notice posted to the state’s Department of Labor website on Dec. 23. The global biopharmaceutical company plans to close the site March 17, with 92 employees being laid off. Athenex representatives could not be reached, but according to the state Department of Labor, the reason for the closing was “economic.”

  • GlobeNewswire

    Athenex Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer

    Oral Paclitaxel combination regimen has graduated in this Phase 2 trial in the triple negative breast cancer subgroupBUFFALO, N.Y., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions announced that collaborators at the Quantum Leap Healthcare Collaborative reported today that the Company’s oral paclitaxel plus encequ

Advertisement
Advertisement